Evidence map›Paper›PMID 40893153›Full record

Article3 Biotech2025

Hasan Çağrı Yıldırım, Fatih Yay, Gökhan Şahin, Fatih Kuş, Şuayib Yalçın

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in 3 Biotech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hasan Çağrı YıldırımFaculty of Medicine, Department of Medical Oncology, Ege University, Izmir, Turkey.ORCID 0000-0003-3060-377X
Fatih YayClinical Biochemistry Laboratory, Nigde Omer Halis Demir University Training and Research Hospital, Nigde, Turkey.
Gökhan ŞahinFaculty of Medicine, Department of Medical Oncology, Ege University, Izmir, Turkey.
Fatih KuşFaculty of Medicine, Deparment of Medical Oncology, Hacettepe University, Ankara, Turkey.
Şuayib YalçınFaculty of Medicine, Deparment of Medical Oncology, Hacettepe University, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer is a common malignancy with a high mortality rate. Improvement in survival has been observed with therapies targeting HER2 and Claudin 18.2 or with immune checkpoint inhibitors. Despite these advancements, the prognosis remains poor. Therefore, there is a need to identify new prognostic biomarkers that may play a role in gastric cancer and then conduct studies that can target these molecules. In this study, bioinformatics databases were utilized to analyze Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-025-04491-3.

Indexed as

BioinformaticsCPNE2 geneGastric cancersPrognostic markers

Identifiers

PMID40893153
PMCPMC12397100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.